Pfizer and Arvinas to jointly develop and commercialise breast cancer drug
Pfizer and Arvinas have collaborated to co-develop and co-commercialise ARV-471, an investigational oral Protac estrogen receptor protein degrader. The estrogen receptor (ER) is a well-known disease driver in